127 related articles for article (PubMed ID: 32356398)
1. Maculopapular rash to S-carboxymethylcysteine-lysine (carbocisteine).
Gomez Torrijos E; Gratacós Gómez AR; Extremera Ortega AM; Gonzalez Jimenez OM; Romo JBJ; Cañas AP; Rodriguez RG
Contact Dermatitis; 2020 Oct; 83(4):313-314. PubMed ID: 32356398
[No Abstract] [Full Text] [Related]
2. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease.
Hooper C; Calvert J
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081
[TBL] [Abstract][Full Text] [Related]
3. [Fixed drug eruption and carbocysteine].
Schmutz JL; Barbaud A; Trechot P
Ann Dermatol Venereol; 2005 Apr; 132(4):403. PubMed ID: 15886580
[No Abstract] [Full Text] [Related]
4. Fixed drug eruption occurring in vitiliginous skin.
Ota M; Tanimura S
J Am Acad Dermatol; 2013 Dec; 69(6):e302-3. PubMed ID: 24238187
[No Abstract] [Full Text] [Related]
5. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
[TBL] [Abstract][Full Text] [Related]
6. S-Carboxymethyl-L-cysteine-induced Fixed Drug Eruption.
Fukuda H; Takahashi M
Acta Derm Venereol; 2019 Jun; 99(7):689-690. PubMed ID: 30938829
[No Abstract] [Full Text] [Related]
7. Carbocisteine: frequent cutaneous adverse effects.
Prescrire Int; 2007 Feb; 16(87):17. PubMed ID: 17326276
[TBL] [Abstract][Full Text] [Related]
8. Drug fever due to S-carboxymethyl-L-cystein: demonstration of a causative agent with patch tests.
Hatakeyama M; Fukunaga A; Shimizu H; Oka M; Horikawa T; Nishigori C
J Dermatol; 2012 Jun; 39(6):555-6. PubMed ID: 21950673
[No Abstract] [Full Text] [Related]
9. Thiodiglycolic acid and dermatological reactions following S-carboxymethyl-L-cysteine administration.
Steventon GB; Mitchell SC
Br J Dermatol; 2006 Feb; 154(2):386-7. PubMed ID: 16433823
[No Abstract] [Full Text] [Related]
10. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
11. Carbocisteine for acute exacerbations of COPD.
Waller P; Suissa S
Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
[No Abstract] [Full Text] [Related]
12. Thiodiglycolic acid as a possible causative agent of fixed drug eruption provoked only after continuous administration of S-carboxymethyl-L-cysteine: case report and review of reported cases.
Adachi A; Sarayama Y; Shimizu H; Yamada Y; Horikawa T
Br J Dermatol; 2005 Jul; 153(1):226-8. PubMed ID: 16029368
[No Abstract] [Full Text] [Related]
13. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
14. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease.
Tatsumi K; Fukuchi Y;
J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906
[No Abstract] [Full Text] [Related]
15. Carbocisteine for acute exacerbations of COPD.
Mohapatra PR; Aggarwal D
Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
[No Abstract] [Full Text] [Related]
16. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life.
Alibašić E; Skopljak A; Čengić A; Krstović G; Trifunović N; Čatić T; Kapo B; Mehić M; Hadžimuratović A
Med Glas (Zenica); 2017 Aug; 14(2):182-188. PubMed ID: 28786969
[TBL] [Abstract][Full Text] [Related]
17. Carbocisteine can scavenge reactive oxygen species in vitro.
Nogawa H; Ishibashi Y; Ogawa A; Masuda K; Tsubuki T; Kameda T; Matsuzawa S
Respirology; 2009 Jan; 14(1):53-9. PubMed ID: 19144049
[TBL] [Abstract][Full Text] [Related]
18. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke.
Sun L; Tang L; Xu Y; Wang S; Li Y; Kang J
Respirology; 2010 Oct; 15(7):1064-71. PubMed ID: 20807377
[TBL] [Abstract][Full Text] [Related]
19. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model.
Song Y; Yu P; Lu JJ; Lu HZ; Zhu L; Yu ZH; Chen HZ; Cui YY
Pulm Pharmacol Ther; 2016 Aug; 39():38-47. PubMed ID: 27328977
[TBL] [Abstract][Full Text] [Related]
20. Accelerated cell-mediated broncho-obstructive reaction to inhaled stepronin: a case report.
Romano A; Di Fonso M; Mormile F; Quaratino D; Giuffreda F; Venuti A
Allergy; 1996 Apr; 51(4):269-71. PubMed ID: 8792926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
